What is Loncar Cancer Immunotherapy ETF (CNCR)?

Loncar Cancer Immunotherapy ETF (CNCR) is an ETF in the Financial Services sector, Asset Management industry. View full analysis on Stocks360.

What is the current price of CNCR?

The current price of CNCR is $9.02. Prices are updated in real time on Stocks360.

What is CNCR's market capitalization?

CNCR's market capitalization is $7,042,924.00, placing it in the small-cap tier.

Loncar Cancer Immunotherapy ETF (CNCR)

ETF analysis · NASDAQ · Financial Services · Asset Management

$9.02

Market Cap

$7.04M

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

0.96

Day Range

$9.02 – $9.02

52-wk Range

$7.88 – $16.27

Avg Volume

N/A

Volume

0.00

Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund in the Financial Services sector. Latest price: $9.02. Market cap $7.04M. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Loncar Cancer Immunotherapy ETF

This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this benchmark index. A minimum of 80% of the fund's overall holdings will consistently be directed towards these specific index components. Notably, this fund operates as a non-diversified investment vehicle.